MedTrace Logo

Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome

NCT03359460 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2026-03-10

No results posted yet for this study

Summary

This phase I trial studies the side effects and best dose of ibrutinib when giving together with lenalidomide in treating patients with myelodysplastic syndrome. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ibrutinib and lenalidomide may work better in treating patients with myelodysplastic syndrome.

Conditions

  • Myelodysplastic Syndrome
  • Previously Treated Myelodysplastic Syndrome
  • Refractory High Risk Myelodysplastic Syndrome
  • Secondary Myelodysplastic Syndrome
  • Therapy-Related Myelodysplastic Syndrome

Interventions

DRUG

Ibrutinib

Given PO

DRUG

Lenalidomide

Given PO

Sponsors & Collaborators

  • Pharmacyclics LLC.

    collaborator INDUSTRY

  • Celgene

    collaborator INDUSTRY

  • National Cancer Institute (NCI)

    collaborator NIH

  • University of California, Davis

    lead OTHER

Principal Investigators

  • Brian Jonas · University of California, Davis

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-01
Primary Completion
2019-08-29
Completion
2019-11-17
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03359460 on ClinicalTrials.gov